View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Uncategorised
May 21, 2020

Ally Bridge Group leads $150m Covid-19 life science funding

By Chloe Kent

Life science investment firm Ally Bridge Group (ABG) has led three US medtech investments amid the Covid-19 pandemic.

Each of the three companies could have a role to play as the pandemic continues.

ABG has led a $25m investment in Vida Health, an all-in-one virtual care platform managing polychronic physical and behavioural conditions such as diabetes, obesity, hypertension and mental health conditions.

The investment group has also led a $60m investment in Rapid Micro Biosystems, a life science tools company that offers products for the detection and data-tracking of bacterial contamination in the manufacturing of pharmaceuticals, biologics, medical devices, water and food processing, and personal care products.

Finally, it has led an investment of a further $66m in Pulmonx, a medical device company specialising in minimally invasive treatment for patients with severe emphysema.

ABG founder and CEO Frank Yu said: “The Covid-19 pandemic is undoubtedly a watershed event for life science and healthcare around the globe, and further strengthens ABG’s commitment to leading high-impact investments in game-changing innovations in this space.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network